Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By

Showing results 371 - 380 of 645

7 July 2022

The Power of Demand Generation

Demand generation increases awareness of and demand for health products or services among a particular intended audience through social and behavior change communication and social marketing techniques. This learning module outlines the key concepts and definitions of demand generation.

Demand Creation/Marketing

External Link
7 July 2022

Health Care Providers as Agents of Change: Integrating PrEP with other sexual and reproductive health services for adolescent girls and young women

Providing integrated HIV PrEP and sexual reproductive health (SRH) care is difficult for many healthcare providers. They face many barriers. Successul integration will require interation and adaptation. O'Malley et al. investigate the structural and motivational barriers that healthcare providers face in providing integrated care to adolescent girls and young women (AGYW).

Research, Service Delivery

External Link
7 July 2022

A community-based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa

This study explores the feasibility and acceptability of providing PrEP to adolescent girls and young women via a community-based mobile health clinic known as the Tutu Teen Truck in Cape Town, South Africa

Research, Service Delivery

External Link
7 July 2022

Sexually Transmitted Infections Among African Women: An opportunity for combination sexually transmitted infection/HIV prevention

The global epidemic of Sexually Transmitted Infections (STIs) in women demands new prevention approaches. This article outlines new strategies which are emerging that offer opportunities for research and program delivery of combination STI/HIV prevention .

Research

External Link
7 July 2022

Project Hope Namibia PrEP Communication Toolkit

Duplicated resource, same as above

Demand Creation/Marketing

External Link
7 July 2022

Synthesis of Post-Exposure Prophylaxis (PEP) Policies in MOSAIC Countries

This brief summarizes the PEP policy landscape, how to address barriers to policy and implementation, and provides recommendations to increase PEP uptake as part of HIV prevention. While it focuses on countries within the MOSAIC consortium, the findings are broadly applicable for ministries of health, implementing partners, providers, and potential PEP users alike.

Normative Guidance/Policies

Document
7 July 2022

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa

This study compares the effectiveness and cost-effectiveness of providing antiretroviral therapy vs PrEP in South Africa

Financing & Costing

External Link
7 July 2022

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa

This study estimates the cost-effectiveness of daily oral PrEP, with a protective effect against the herpes simplex virus as well as HIV, among HIV serodifferent couples in South Africa

Financing & Costing

External Link
7 July 2022

Dapivirine Vaginal Ring for HIV Prevention: Modeling health outcomes, drug resistance and cost‐effectiveness

This paper evaluates the potential epidemiological impact and cost-effectiveness of dapivirine vaginal ring PrEP among 22- to 45-year-old women in KwaZulu-Natal, South Africa.

Financing & Costing, Research

External Link
7 July 2022

FDA approves first drug for reducing the risk of sexually acquired HIV infection

This article from July 16, 2012 announces the U.S. Food and Drug Administration's approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Normative Guidance/Policies

External Link